clinical trial · NCT04658147
Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·phase1·active not recruiting·n = 31
Hepatocellular CarcinomaNivolumabRelatlimab
brief summary
The purpose of this study is to determine the safety and tolerability of neoadjuvant/adjuvant Nivolumab or Nivolumab plus Relatlimab in patients with HCC.
started
May 28, 2021
primary completion
Sep 2, 2025
completion
Jun 1, 2030
last updated
Jun 11, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol